We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
U.K. startup Izana has started recruiting patients into its phase 2a trial of its anti-GM-CSF antibody namilumab in ankylosing spondylitis, a severe form of arthritis affecting the spine.